Preclinical studies have shown that HAD-B1 has an anti-lung-cancer effect in xenograft animal model experiments using A549 lung cancer cells and A549/CR cells.[7] The results revealed that the activities of caspase-3, -8, and -9 in the HAD-B1-treated group were generally increased in the same way as they were in the afatinib group, suggesting its potential as a novel therapeutic agent for use in afatinib plus HAD-B1 combined therapy for inhibiting acquired resistance. Here, CASP3 is linked to lung carcinoma.